Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader

An, 2018, Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs, EBioMedicine, 36, 553, 10.1016/j.ebiom.2018.09.005

Baker, 2015, Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors, Oncotarget, 6, 32646, 10.18632/oncotarget.5066

Barnash, 2017, Discovery of peptidomimetic ligands of EED as allosteric inhibitors of PRC2, ACS Comb. Sci., 19, 161, 10.1021/acscombsci.6b00174

Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat. Chem. Biol., 11, 611, 10.1038/nchembio.1858

Bracken, 2003, EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer, EMBO J., 22, 5323, 10.1093/emboj/cdg542

Brooun, 2016, Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance, Nat. Commun., 7, 11384, 10.1038/ncomms11384

Buckley, 2015, HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins, ACS Chem. Biol., 10, 1831, 10.1021/acschembio.5b00442

Cardote, 2017, Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex, Structure, 25, 901, 10.1016/j.str.2017.04.009

Chan, 2018, Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds, J. Med. Chem., 61, 504, 10.1021/acs.jmedchem.6b01912

Cromm, 2017, Targeted protein degradation: from chemical biology to drug discovery, Cell Chem. Biol., 24, 1181, 10.1016/j.chembiol.2017.05.024

Cyrus, 2011, Impact of linker length on the activity of PROTACs, Mol. Biosyst., 7, 359, 10.1039/C0MB00074D

Dilworth, 2019, Targeting protein methylation: from chemical tools to precision medicines, Cell. Mol. Life Sci., 76, 2967, 10.1007/s00018-019-03147-9

Ferrari, 2014, Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity, Mol. Cell, 53, 49, 10.1016/j.molcel.2013.10.030

Fischer, 2014, Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide, Nature, 512, 49, 10.1038/nature13527

Frost, 2016, Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition, Nat. Commun., 7, 1, 10.1038/ncomms13312

Gadd, 2017, Structural basis of PROTAC cooperative recognition for selective protein degradation, Nat. Chem. Biol., 13, 514, 10.1038/nchembio.2329

Gan, 2018, Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential, Biomark Res., 6, 10, 10.1186/s40364-018-0122-2

Genta, 2019, BET and EZH2 inhibitors: novel approaches for targeting cancer, Curr. Oncol. Rep., 21, 13, 10.1007/s11912-019-0762-x

Gibaja, 2016, Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors, Oncogene, 35, 558, 10.1038/onc.2015.114

Girardini, 2019, Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs, Bioorg. Med. Chem., 27, 2466, 10.1016/j.bmc.2019.02.048

He, 2017, The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex, Nat. Chem. Biol., 13, 389, 10.1038/nchembio.2306

Hsu, 2020, EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex, Cell Chem. Biol., 10.1016/j.chembiol.2019.11.004

Huang, 2017, Discovery of first-in-class, potent, and orally bioavailable embryonic Ectoderm development (EED) inhibitor with robust anticancer efficacy, J. Med. Chem., 60, 2215, 10.1021/acs.jmedchem.6b01576

Huang, 2018, A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader, Cell Chem. Biol., 2, 88, 10.1016/j.chembiol.2017.10.005

Hyun, 2017, Writing, erasing and reading histone lysine methylations, Exp. Mol. Med., 49, e324, 10.1038/emm.2017.11

Jiao, 2015, Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2, Science, 350, aac4383, 10.1126/science.aac4383

Justin, 2016, Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2, Nat. Commun., 7, 11316, 10.1038/ncomms11316

Kasinath, 2018, Structures of human PRC2 with its cofactors AEBP2 and JARID2, Science, 359, 940, 10.1126/science.aar5700

Konze, 2013, An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1, ACS Chem. Biol., 8, 1324, 10.1021/cb400133j

Lee, 2018, Allosteric activation dictates PRC2 activity independent of its recruitment to chromatin, Mol. Cell, 70, 422, 10.1016/j.molcel.2018.03.020

Liu, 2015, Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer, J. Cancer Res. Clin. Oncol., 141, 661, 10.1007/s00432-014-1854-5

Maniaci, 2017, Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation, Nat. Commun., 8, 830, 10.1038/s41467-017-00954-1

Margueron, 2011, The polycomb complex PRC2 and its mark in life, Nature, 469, 343, 10.1038/nature09784

Margueron, 2008, Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms, Mol. Cell, 32, 503, 10.1016/j.molcel.2008.11.004

McCabe, 2012, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, 492, 108, 10.1038/nature11606

Montgomery, 2007, Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation, J. Mol. Biol., 374, 1145, 10.1016/j.jmb.2007.10.040

Mullard, 2019, First targeted protein degrader hits the clinic, Nat. Rev. Drug Discov.

Peng, 2009, Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells, Cell, 139, 1290, 10.1016/j.cell.2009.12.002

Poepsel, 2018, Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes, Nat. Struct. Mol. Biol., 25, 154, 10.1038/s41594-018-0023-y

Qi, 2017, An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED, Nat. Chem. Biol., 13, 381, 10.1038/nchembio.2304

Rectenwald, 2019, A general TR-FRET assay platform for high-throughput screening and characterizing inhibitors of methyl-lysine reader proteins, SLAS Discov., 24, 693, 10.1177/2472555219844569

Riching, 2018, Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action, ACS Chem. Biol., 13, 2758, 10.1021/acschembio.8b00692

Rizq, 2017, Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition, Clin. Cancer Res., 23, 4817, 10.1158/1078-0432.CCR-16-2735

Salami, 2017, Waste disposal––an attractive strategy for cancer therapy, Science, 355, 1163, 10.1126/science.aam7340

Shortt, 2017, A chemical probe toolbox for dissecting the cancer epigenome, Nat. Rev. Cancer, 17, 160, 10.1038/nrc.2016.148

Smith, 2019, Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase, Nat. Commun., 10, 1, 10.1038/s41467-018-08027-7

Veneti, 2017, Polycomb repressor complex 2 in genomic instability and cancer, Int. J. Mol. Sci., 119, 1

Vizcaino, 2013, The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013, Nucleic Acids Res., 41, D1063, 10.1093/nar/gks1262

Xu, 2015, Targeting EZH2 and PRC2 dependence as novel anticancer therapy, Exp. Hematol., 43, 698, 10.1016/j.exphem.2015.05.001

Yuan, 2018, Total synthesis, structural revision and biological evaluation of γ-elemene-type sesquiterpenes, Org. Biomol. Chem., 16, 7843, 10.1039/C8OB02005A

Zou, 2019, The PROTAC technology in drug development, Cell Biochem. Funct., 37, 21, 10.1002/cbf.3369